Your Research
& Development

Make your hits come true

Last publication

Identification of new enterosynes using prebiotics: roles of bioactive (...)



Enterosys is a biotech compagny specialized in high-quality preclinical evaluation services.
Our team of physiologists and pharmacologists offers a unique platform with a wide range of in vitro and in vivo assays.
Founded in 2017, Enterosys has developed its own R&D projects (or pipeline) in addition to its partnering expertise in preclinical research.


Our corporate culture is driven by the flexibility, responsiveness and quality of our interactions with our customers.


We conduct studies using validated GLP-like protocols and project management methods

In depth

We foster in-depth scientific discussions focused on understanding customers needs and offering tailor-made solutions


We strive to deliver the best results, regardless of the magnitude of the challenge

Maxime Fontanié

CEO and co-founder

Maxime Fontanié

An entrepreneur with a degree in engineering and an executive MBA, Max has broad expertise in pharmaceutical R&D, finance, strategy and business development. He began his career at the French academic institute INSERM, then moved to Sanofi in 2002 where he conducted a number of drug development projects as team leader, international project manager and pharmacologic scientist. In 2014, Max founded Vibiosphen S.A., a biotech company specialized in nosocomial infection. His motto is: “Yes we care”

Anne Abot


Dr Anne Abot

After a PhD at the University Paul Sabatier in Toulouse (France), in the field of metabolic and cardiovascular diseases, she worked with Pr Knauf and developed a strong expertise in gut-brain axis and associated pathologies, especially type 2 diabetes. Currently, she is doing a master degree in management of innovation in continuing education. Her motto is: “The impossible is what takes a little longer”

Claude Knauf

Co-founder and President of Scientific Advisory Board

Pr Claude Knauf

Claude is Professor at the University Paul Sabatier in Toulouse (France) and researcher at the INSERM Laboratory. He is the co-director with Pr. P.D.Cani of the European Associated Laboratory: “NeuroMicrobiota” (France/Belgium) that has an internationally recognition in the field of metabolic diseases and has discovered the first enterosynes. Claude is particularly focused on the role of reactive nitrogen/oxygen species in the control of tissue/cell function. His motto is: “Why not”.

Patrice Cani


Pr Patrice Cani

Patrice is Senior Researcher from FRS-FNRS, group leader at the Louvain Drug Research Institute, Université Catholique de Louvain (Brussels, Belgium) and co-director with Prof. C.Knauf of the “NeuroMicrobiota” Lab (INSERM, Toulouse, France/UCL). Patrice is internationally recognized in the field of microbiota and metabolic disorders and he is recipient of prestigious grants (WELBIO investigator, ERC Starting Grant 2013 (ENIGMO), PoC ERC grant 2016,…). He is also co-founder, CSO and director of A-Mansia Biotech SA. His motto is: “In Gut We Trust”.

Rémy Burcelin


Pr Rémy Burcelin

Rémy is Research Director at the INSERM Institute in Toulouse. He has been involved in the identification of the molecular mechanisms responsible for the development of metabolic diseases. He pioneered the discovery of the molecular mechanisms of enteric glucose sensing, notably the role of GLP1 and glucose transporters, leading to the control of the gut brain axis and of the corresponding physiological functions involved in the glycemic control. He is co-founder of several biotech companies (Physiogenex, Vaiomer, Aviwell). His motto is: “Make the intestine great again”.

Our clients

Pierre Fabre

Our partners

BPI France
Hopital universitaire de Gérone
Horizon 2020
Région Occitanie
Université Paul Sabatier